Acro Biomedical (ACBM) replaces KCCW with Weinberg as auditor amid going concern note
Rhea-AI Filing Summary
Acro Biomedical Co., Ltd. reported a change in its independent auditor. On January 4, 2026, the company dismissed KCCW Accountancy Corp. as its independent registered public accounting firm and, on the same date, its board approved the engagement of Weinberg & Company as the new independent registered accounting firm.
The company states that for the fiscal years ended December 31, 2024 and 2023, and for subsequent interim periods through KCCW’s dismissal, there were no disagreements with KCCW on accounting principles, financial statement disclosure, or audit scope or procedure. KCCW’s reports for those years contained no adverse opinion or disclaimer and were not qualified, but did include an explanatory paragraph about uncertainty regarding Acro Biomedical’s ability to continue as a going concern. The company has asked KCCW to provide a letter to the SEC indicating whether it agrees with these disclosures.
Positive
- None.
Negative
- None.
Insights
Acro Biomedical replaces its auditor without reported disagreements, but prior audits flagged going-concern uncertainty.
Acro Biomedical dismissed KCCW Accountancy Corp. as its independent auditor and approved Weinberg & Company as the new firm effective January 4, 2026. The company explicitly notes that during the fiscal years ended December 31, 2024 and 2023, and interim periods through the dismissal date, it had no disagreements with KCCW on accounting principles, disclosures, or audit scope that would have been referenced in KCCW’s reports.
KCCW’s audit opinions for those years were clean in terms of audit and accounting issues, but they did include an explanatory paragraph highlighting uncertainty about Acro Biomedical’s ability to continue as a going concern. This signals that KCCW viewed the company’s financial condition or funding profile as raising doubt about ongoing operations, even though the financial statements were still fairly presented. The company also states it did not consult Weinberg on specific accounting treatments or expected audit opinions before this engagement.
The change in auditor, combined with the prior going-concern emphasis, makes future audit reports from Weinberg important reference points once the December 31, 2025 financial statements are audited. Those reports will show whether the going-concern uncertainty persists or changes relative to what KCCW previously disclosed.
8-K Event Classification
FAQ
What auditor change did Acro Biomedical (ACBM) report in this 8-K?
Acro Biomedical reported that on January 4, 2026 it dismissed KCCW Accountancy Corp. as its independent registered public accounting firm and its board approved the engagement of Weinberg & Company as the new independent registered accounting firm.
Did Acro Biomedical (ACBM) report any disagreements with KCCW as its former auditor?
The company states that during the fiscal years ended December 31, 2024 and 2023 and the interim periods through KCCW’s dismissal, there were no disagreements with KCCW on accounting principles or practices, financial statement disclosure, or auditing scope or procedure that would have been mentioned in KCCW’s audit reports.
What did KCCW’s prior audit reports say about Acro Biomedical’s financial condition?
KCCW’s reports on Acro Biomedical’s financial statements for the years ended December 31, 2024 and 2023 contained no adverse opinion or disclaimer and were not qualified or modified as to uncertainty, audit scope, or accounting principles. However, they included an explanatory paragraph about uncertainty regarding the company’s ability to continue as a going concern.
Did Acro Biomedical (ACBM) consult Weinberg & Company before appointing it as auditor?
The company states that during the fiscal year ended December 31, 2025 and the interim period from January 1, 2025 to the report date, neither Acro Biomedical nor anyone acting on its behalf consulted Weinberg & Company about the application of accounting principles to specific transactions, the type of audit opinion that might be issued, or any reportable events under Item 304(a)(1)(v) of Regulation S-K.
How is KCCW involved after its dismissal as Acro Biomedical’s auditor?
Acro Biomedical has provided KCCW with a copy of the disclosures about the auditor change and requested that KCCW furnish a letter to the Securities and Exchange Commission stating whether it agrees with the company’s statements in Item 4.01. This letter is identified as Exhibit 16.1 to the report.